Immediate Impact
48 standout
Citing Papers
Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy
2025 Standout
From chaos to order: optimizing fecal microbiota transplantation for enhanced immune checkpoint inhibitors efficacy
2025 Standout
Works of Mohammed Harb being referenced
CCTG CO.26: Updated analysis and impact of plasma-detected microsatellite stability (MSS) and tumor mutation burden (TMB) in a phase II trial of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with refractory metastatic colorectal carcinoma (rmCRC).
2019
CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC).
2019
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Mohammed Harb | 124 | 24 | 36 | 68 | 44 | 9 | 186 | |
| Amanda Goldrick | 154 | 26 | 18 | 79 | 43 | 10 | 223 | |
| Shyamprasad Deraje Vasudeva | 71 | 21 | 38 | 142 | 65 | 8 | 224 | |
| Aurélie Vogt | 89 | 60 | 20 | 93 | 65 | 12 | 232 | |
| Nazir Jamal | 100 | 27 | 19 | 90 | 65 | 9 | 267 | |
| Catherine Vézina | 153 | 29 | 38 | 54 | 43 | 11 | 274 | |
| M. H. Le | 136 | 38 | 50 | 91 | 52 | 9 | 265 | |
| Su Young Kim | 75 | 29 | 71 | 109 | 48 | 11 | 231 | |
| Surita Dalal | 48 | 17 | 54 | 72 | 69 | 11 | 180 | |
| Michal Kubiak | 115 | 36 | 18 | 49 | 49 | 10 | 193 | |
| Andy Protter | 156 | 37 | 27 | 149 | 58 | 7 | 256 |
All Works
Loading papers...